Skip to main content
Article
Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density
Illawarra Health and Medical Research Institute
  • Jiamei Lian, University of Wollongong
  • Xu-Feng Huang, University of Wollongong
  • Nagesh Pai, University of Wollongong
  • Chao Deng, University of Wollongong
Publication Date
1-1-2013
RIS ID
82413
Publication Details

Lian, J., Huang, X., Pai, N. & Deng, C. 2013, 'Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 47, pp. 62-68.

Abstract
Olanzapine is widely used in treating multiple domains of schizophrenia symptoms but induces serious metabolic side-effects. Recent evidence has showed that co-treatment of betahistine (a histaminergic H1 receptor agonist and H3 receptor antagonist) is effective for preventing olanzapine-induced weight gain/obesity, however it is not clear whether this co-treatment affects on the primary therapeutic receptor binding sites of olanzapine such as serotonergic 5-HT2A receptors (5-HT2AR) and dopaminergic D2 receptors (D2R). Therefore, this study investigated the effects of this co-treatment on 5-HT2AR, 5-HT transporter (5-HTT) and D2R bindings in various brain regions involved in antipsychotic efficacy. Female Sprague Dawley rats were administered orally (t.i.d.) with either olanzapine (1 mg/kg), betahistine (2.7 mg/kg), olanzapine plus betahistine (O + B), or vehicle (control) for 2 weeks. Quantitative autoradiography was used to detect the density of [3H]ketanserin, [3H]paroxetine and [3H]raclopride binding site to 5-HT2AR, 5-HTT and D2R. Compared to the controls, olanzapine significantly decreased [3H]ketanserin bindings to 5-HT2AR in the prefrontal cortex, cingulate cortex, and nucleus accumbens. Similar changes in 5-HT2AR bindings in these nuclei were also observed in the O + B co-treatment group. Olanzapine also significantly decreased [3H]paroxetine binding to 5-HTT in the ventral tegmental area and substantia nigra, however, both olanzapine only and O + B co-treatment did not affect [3H]raclopride binding to D2R. The results confirmed the important role of 5-HT2AR in the efficacy of olanzapine, which is not influenced by the O + B co-treatment. Therefore, betahistine co-treatment would be an effective combination therapy to reduce olanzapine-induced weight gain side-effects without affecting olanzapine's actions on 5-HT2AR transmissions.
Grant Number
NHMRC/1027493
Citation Information
Jiamei Lian, Xu-Feng Huang, Nagesh Pai and Chao Deng. "Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density" (2013) p. 62 - 68
Available at: http://works.bepress.com/xhuang/200/